• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Open Forum Infect Dis . COVID-19 Patient-Reported Symptoms Using FLU-PRO Plus in a Cohort Study: Associations With Infecting Genotype, Vaccine Hist

tetano

Editor, Senior Moderator
Open Forum Infect Dis


. 2022 Jun 7;9(7):ofac275.
doi: 10.1093/ofid/ofac275. eCollection 2022 Jul.
COVID-19 Patient-Reported Symptoms Using FLU-PRO Plus in a Cohort Study: Associations With Infecting Genotype, Vaccine History, and Return to Health


Stephanie A Richard[SUP] 1 [/SUP], Nusrat J Epsi[SUP] 1 [/SUP], David A Lindholm[SUP] 2 [/SUP], Allison M W Malloy[SUP] 3 [/SUP], Ryan C Maves[SUP] 1 [/SUP], Catherine M Berjohn[SUP] 3 [/SUP], Tahaniyat Lalani[SUP] 1 [/SUP], Alfred G Smith[SUP] 4 [/SUP], Rupal M Mody[SUP] 5 [/SUP], Anuradha Ganesan[SUP] 1 [/SUP], Nikhil Huprikar[SUP] 3 [/SUP], Rhonda E Colombo[SUP] 1 [/SUP], Christopher J Colombo[SUP] 3 [/SUP], Cristian Madar[SUP] 6 [/SUP], Milissa U Jones[SUP] 3 [/SUP], Derek T Larson[SUP] 7 [/SUP], Evan C Ewers[SUP] 8 [/SUP], Samantha Bazan[SUP] 9 [/SUP], Anthony C Fries[SUP] 10 [/SUP], Carlos J Maldonado[SUP] 11 [/SUP], Mark P Simons[SUP] 1 [/SUP], Julia S Rozman[SUP] 1 [/SUP], Liana Andronescu[SUP] 1 [/SUP], Katrin Mende[SUP] 1 [/SUP], David R Tribble[SUP] 1 [/SUP], Brian K Agan[SUP] 1 [/SUP], Timothy H Burgess[SUP] 1 [/SUP], Simon D Pollett[SUP] 1 [/SUP], John H Powers 3rd[SUP] 12 [/SUP], EPICC COVID-19 Cohort Study Group



Collaborators, Affiliations

Abstract

Background: Patient-reported outcomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are an important measure of the full burden of coronavirus disease (COVID). Here, we examine how (1) infecting genotype and COVID-19 vaccination correlate with inFLUenza Patient-Reported Outcome (FLU-PRO) Plus score, including by symptom domains, and (2) FLU-PRO Plus scores predict return to usual activities and health.
Methods: The epidemiology, immunology, and clinical characteristics of pandemic infectious diseases (EPICC) study was implemented to describe the short- and long-term consequences of SARS-CoV-2 infection in a longitudinal, observational cohort. Multivariable linear regression models were run with FLU-PRO Plus scores as the outcome variable, and multivariable Cox proportional hazards models evaluated effects of FLU-PRO Plus scores on return to usual health or activities.
Results: Among the 764 participants included in this analysis, 63% were 18-44 years old, 40% were female, and 51% were White. Being fully vaccinated was associated with lower total scores (β = -0.39; 95% CI, -0.57 to -0.21). The Delta variant was associated with higher total scores (β = 0.25; 95% CI, 0.05 to 0.45). Participants with higher FLU-PRO Plus scores were less likely to report returning to usual health and activities (health: hazard ratio
, 0.46; 95% CI, 0.37 to 0.57; activities: HR, 0.56; 95% CI, 0.47 to 0.67). Fully vaccinated participants were more likely to report returning to usual activities (HR, 1.24; 95% CI, 1.04 to 1.48).
Conclusions: Full SARS-CoV-2 vaccination is associated with decreased severity of patient-reported symptoms across multiple domains, which in turn is likely to be associated with earlier return to usual activities. In addition, infection with the Delta variant was associated with higher FLU-PRO Plus scores than previous variants, even after controlling for vaccination status.

Keywords: COVID-19; SARS-CoV-2; patient-reported outcomes; symptoms; vaccine breakthrough.
 
Back
Top Bottom